ESSA Pharma, Inc. :EPI-CA: Earnings Analysis: Q1, 2017 By the Numbers

ESSA Pharma, Inc. reports financial results for the quarter ended December 31, 2016.


  • Summary numbers: Revenues of CAD 0 million, Net Earnings of CAD 1.95 million.
  • The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.
  • EPI-CA‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful to make this analysis between operating advantage (ROE) and growth expectations (as suggested by P/E or P/EBITDA).
  • Cash and Cash equivalents were up this period to 14.56 million compared to 3.62 million in the same period last year.
  • With debt at a relatively low 12.54% of its enterprise value compared to an overall benchmark of 25% (Note: The peer median is currently 6.27%), and relatively tight interest coverage level of -166.84x, EPI-CA would have a hard time raising much additional debt. Thus, the company is classified as having Limited Flexibility when it comes to raising more debt.
  • Of the 4 chosen peers for the company, only 2 of the stocks have an outstanding debt balance. Companies with no debt include OMED-US and OHRP-US.
  • Net income of 1.95 million this period compared to a net income of -5.53 million last period. This is a growth of 135.36% over the previous period. In comparison, the peer group grew at -5.12%

Access our Ratings and Scores for ESSA Pharma, Inc.

Earnings Growth QOQ %
Cash & ST Investments

Access our Ratings and Scores for ESSA Pharma, Inc.

Company Profile

ESSA Pharma, Inc. is a pharmaceutical company. It focuses on the development of small molecule drugs for advanced prostate cancer. The company develops drugs that selectively block the N-terminal domain of the androgen receptor that is required for the growth and survival of most prostate cancer. ESSA Pharma was founded by Marianne Sadar and Raymond Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of EPI-CA.